In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...

People who took both Zepbound and an anti-inflammatory drug saw a greater improvement of their psoriatic arthritis symptoms.

Eli Lilly is riding the wave of a booming weight management market. Eli Lilly's tirzepatide, sold under the brand names ...

Tirzepatide noninferior to dulaglutide with respect to composite of death from cardiovascular causes, myocardial infarction, ...

Arrowhead Pharmaceuticals has reported early-phase data on a pair of gene silencing drug candidates in obesity, posting ...

Experts emphasized that obesity is a chronic, relapsing condition and lifelong therapy—in some form—will be necessary.

Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the novel TOGETHER-PsA open-label Phase 3b ...

Arrowhead heralded the results as proof of concept that inhibiting the Activin E pathway can improve body composition and ...

Tirzepatide can cost $500 to $1,900 a month without insurance. More affordable tirzepatide alternatives include semaglutide, ...

The retrospective study could not determine whether some patients were more likely than others to keep off the weight.

Nausea is the most common tirzepatide side effect. In Zepbound clinical trials, 25 to 28 percent of people reported nausea. Tirzepatide might cause nausea because it ...

People taking weight-loss drugs are likely to regain the weight they have lost within two years of stopping the medications, ...